S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NYSE:BIO

Bio-Rad Laboratories Stock Forecast, Price & News

$588.34
-6.49 (-1.09 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$584.58
Now: $588.34
$601.91
50-Day Range
$541.87
MA: $587.05
$629.12
52-Week Range
$309.38
Now: $588.34
$648.39
Volume180,741 shs
Average Volume245,785 shs
Market Capitalization$17.55 billion
P/E Ratio5.04
Dividend YieldN/A
Beta0.83
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Bio-Rad Laboratories logo

MarketRank

Overall MarketRank

1.30 out of 5 stars

Medical Sector

692nd out of 1,922 stocks

Analytical Instruments Industry

14th out of 29 stocks

Analyst Opinion: 1.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000
Employees8,120
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.31 billion
Cash Flow$6.97 per share
Book Value$192.32 per share

Profitability

Net Income$1.76 billion

Miscellaneous

Market Cap$17.55 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$588.34
-6.49 (-1.09 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

How has Bio-Rad Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Bio-Rad Laboratories' stock was trading at $345.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIO stock has increased by 70.1% and is now trading at $588.34.
View which stocks have been most impacted by COVID-19
.

Is Bio-Rad Laboratories a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bio-Rad Laboratories stock.
View analyst ratings for Bio-Rad Laboratories
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Bio-Rad Laboratories?

Wall Street analysts have given Bio-Rad Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Rad Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories CEO Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among Bio-Rad Laboratories' employees.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Bio-Rad Laboratories
.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its quarterly earnings results on Thursday, October, 29th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $1.85 by $1.15. The medical research company earned $647.26 million during the quarter, compared to the consensus estimate of $567.35 million. Bio-Rad Laboratories had a net margin of 147.91% and a trailing twelve-month return on equity of 3.77%. The company's revenue for the quarter was up 15.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.61 earnings per share.
View Bio-Rad Laboratories' earnings history
.

What price target have analysts set for BIO?

4 brokerages have issued 12 month price targets for Bio-Rad Laboratories' stock. Their forecasts range from $430.00 to $675.00. On average, they expect Bio-Rad Laboratories' share price to reach $609.20 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price.
View analysts' price targets for Bio-Rad Laboratories
or view Wall Street analyst' top-rated stocks.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the following people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 71, Pay $2.12M)
  • Mr. Ilan Daskal, Exec. VP & CFO (Age 55, Pay $754.23k)
  • Dr. Andrew J. Last, Exec. VP & COO (Age 61, Pay $825.67k)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 59, Pay $663.07k)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 66, Pay $769.91k)
  • Mr. Ajit Ramalingam, Sr. VP & Chief Accounting Officer (Age 48)
  • Diane Dahowski, Sr. VP of Global Technology & Systems
  • Mr. Timothy S. Ernst, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Colleen Corey, Sr. VP of Global HR
  • Lee Boyd, Sr. VP of Global Commercial Operations - Asia Pacific

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.44%), Ardevora Asset Management LLP (0.32%), Columbus Circle Investors (0.10%), New York State Teachers Retirement System (0.07%), Hexavest Inc. (0.05%) and Crossmark Global Holdings Inc. (0.02%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Giovanni Magni, James R Stark, John Hertia, Michael Crowley, Ronald W Hutton and Timothy S Ernst.
View institutional ownership trends for Bio-Rad Laboratories
.

Which major investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Ardevora Asset Management LLP, Hexavest Inc., Pacer Advisors Inc., New York State Teachers Retirement System, Procyon Private Wealth Partners LLC, Sowell Financial Services LLC, and Gateway Investment Advisers LLC. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Giovanni Magni, Michael Crowley, and Ronald W Hutton.
View insider buying and selling activity for Bio-Rad Laboratories
or view top insider-selling stocks.

Which major investors are buying Bio-Rad Laboratories stock?

BIO stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Crossmark Global Holdings Inc., Exchange Traded Concepts LLC, Strategic Investment Advisors MI, State of Alaska Department of Revenue, Kestra Advisory Services LLC, Redpoint Investment Management Pty Ltd, and Janney Montgomery Scott LLC.
View insider buying and selling activity for Bio-Rad Laboratories
or or view top insider-buying stocks.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $588.34.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $17.55 billion and generates $2.31 billion in revenue each year. The medical research company earns $1.76 billion in net income (profit) each year or $7.06 on an earnings per share basis. Bio-Rad Laboratories employs 8,120 workers across the globe.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is www.bio-rad.com.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.